nach oben

Current Atherosclerosis Reports

Erschienen in:

29.07.2022 | Genetics and Genomics (R.A. Hegele and L. Brunham, Section Editors)

Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond

verfasst von: Nabil G. Seidah, Damien Garçon

Erschienen in: Current Atherosclerosis Reports | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Since the discovery of PCSK9 in 2003, this proprotein convertase was shown to target specific receptors for degradation in endosomes/lysosomes, including LDLR and other family members and hence to enhance the levels of circulating LDL-cholesterol (LDLc). Accordingly, inhibitors of PCSK9, including monoclonal antibodies blocking its circulating activity and siRNA silencers of its hepatic expression, are now used in clinics worldwide to treat hypercholesterolemia patients effectively and safely in combination with statins and/or ezetimibe. These powerful treatments reduce the incidence of atherosclerosis by at least 20%. Since 2008, novel targets of PCSK9 began to be defined, thereby expanding its roles beyond LDLc regulation into the realm of inflammation, pathogen infections and cellular proliferation in various cancers and associated metastases.

Recent Findings

Some pathogens such as dengue virus exploit the ability of PCSK9 to target the LDLR for degradation to enhance their ability to infect cells. Aside from increasing the degradation of the LDLR and its family members VLDLR, ApoER2 and LRP1, circulating PCSK9 also reduces the levels of other receptors such as CD36 (implicated in fatty acid uptake), oxidized LDLR receptor (that clears oxidized LDLc) as well as major histocompatibility class-I (MHC-I) receptors (implicated in the immune response to antigens). Thus, these novel targets provided links between PCSK9 and inflammation/atherosclerosis, viral infections and cancer/metastasis. The functional activities of PCSK9, accelerated the development of novel therapies to inhibit PCSK9 functions, including small molecular inhibitors, long-term vaccines, and possibly CRISPR-based silencing of hepatic expression of PCSK9.

Summary

The future of inhibitors/silencers of PCSK9 function or expression looks bright, as these are expected to provide a modern armamentarium to treat various pathologies beyond hypercholesterolemia and its effects on atherosclerosis.

Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003;100(3):928–33.PubMedPubMedCentralCrossRef

Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–6.PubMedCrossRef

Seidah NG. The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer. J Lipid Res. 2021;62:100130.PubMedPubMedCentralCrossRef

Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11(5):367–83.PubMedCrossRef

Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A. 2004;101(18):7100–5.PubMedPubMedCentralCrossRef

McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem. 2007;282(29):20799–803.PubMedCrossRef

Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283(4):2363–72.PubMedCrossRef

Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol. 2007;14(5):413–9.PubMedCrossRef

Piper DE, Jackson S, Liu Q, et al. The crystal structure of PCSK9 a regulator of plasma LDL-cholesterol. Structure. 2007;15(5):545–52.PubMedCrossRef

10.

Surdo PL, Bottomley MJ, Calzetta A, et al. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep. 2011;12(12):1300–5.PubMedPubMedCentralCrossRef

11.

Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282(25):18602–12.PubMedCrossRef

12.

Nassoury N, Blasiole DA, Tebon OA, et al. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic. 2007;8(6):718–32.PubMedCrossRef

13.

Seidah NG, Prat A: The multifaceted biology of PCSK9. Endocr Rev 2021;43(3):558–82.

14.

Jang HD, Lee SE, Yang J, et al. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. Eur Heart J. 2020;41(2):239–52.PubMedCrossRef

15.

Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161.PubMedCrossRef

16.

Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A. 2005;102(15):5374–9.PubMedPubMedCentralCrossRef

17.

Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008;48(2):646–54.PubMedCrossRef

18.

Mayne J, Dewpura T, Raymond A, et al. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin Chem. 2011;57(10):1415–23.PubMedCrossRef

19.

Lebeau PF, Wassef H, Byun JH, et al: The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury. J Clin Invest 2021;131(2):e128650.

20.

Seidah NG, Prat A, Pirillo A, Catapano AL, Norata GD. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. Cardiovasc Res. 2019;115(3):510–8.PubMedPubMedCentralCrossRef

21.

Rosenson RS, Hegele RA, Koenig W. Cholesterol-lowering agents. Circ Res. 2019;124(3):364–85.PubMedCrossRef

22.

Lehoux D, Far AR, Kallend D, Wijngaard PLJ, Zerler B. Evaluation of the distribution and excretion of [(14)C]-inclisiran following single subcutaneous administration in cynomolgus monkeys. Toxicol Appl Pharmacol. 2022;443:115978.PubMedCrossRef

23.

Gennemark P, Walter K, Clemmensen N, et al: An oral antisense oligonucleotide for PCSK9 inhibition. Sci Transl Med 2021;13(593):eabe9117

24.

Tucker TJ, Embrey MW, Alleyne C, et al. A series of novel, highly potent, and orally bioavailable next-generation tricyclic peptide PCSK9 inhibitors. J Med Chem. 2021;64(22):16770–800.PubMedCrossRef

25.

Musunuru K, Chadwick AC, Mizoguchi T, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429–34.PubMedCrossRef

26.

Momtazi-Borojeni AA, Pirro M, Xu S, Sahebkar A. PCSK9 inhibition-based therapeutic approaches: an immunotherapy perspective. Curr Med Chem. 2022;29(6):980–99.PubMedCrossRef

27.

Deedwania P, Murphy SA, Scheen A, et al. Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the FOURIER randomized clinical trial. JAMA Cardiol. 2021;6(2):139–47.PubMedCrossRef

28.

Ray KK, Colhoun HM, Szarek M, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):618–28.PubMedCrossRef

29.

Brandt WE, Buescher EL, Hetrick FM. Production and characterization of arbovirus antibody in mouse ascitic fluid. Am J Trop Med Hyg. 1967;16(3):339–47.PubMedCrossRef

30.

Brandts J, Ray KK. Clinical implications and outcomes of the ORION phase III trials. Future Cardiol. 2021;17(5):769–77.PubMedCrossRef

31.

Ostadal P, Steg PG, Poulouin Y, et al. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2022;10(5):330–40.PubMedCrossRef

32.

Nicholls SJ, Kataoka Y, Nissen SE, et al: Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging 2022;15(7):1308–21.

33.

Desita SR, Hariftyani AS, Jannah AR, Setyobudi AK, Oktaviono YH: PCSK9 and LRP6: potential combination targets to prevent and reduce atherosclerosis. J Basic Clin Physiol Pharmacol 2022. https://doi.org/10.1515/jbcpp-2021-0291

34.

Libby P. Inflammation during the life cycle of the atherosclerotic plaque. Cardiovasc Res. 2021;117(13):2525–36.PubMedPubMedCentral

35.

Liu A, Frostegård J: PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque. J Intern Med 2018 (in press): https://doi.org/10.1111/joim.12758.

36.

Frostegård J. The role of PCSK9 in inflammation, immunity, and autoimmune diseases. Expert Rev Clin Immunol. 2022;18(1):67–74.PubMedCrossRef

37.

Tang Z, Jiang L, Peng J, et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages. Int J Mol Med. 2012;30(4):931–8.PubMedCrossRef

38.

Ding Z, Liu S, Wang X, et al. Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc Res. 2015;107:556–67.PubMedCrossRef

39.

Kim K, Shim D, Lee JS, et al. Transcriptome analysis reveals nonfoamy rather than foamy plaque macrophages are proinflammatory in atherosclerotic murine models. Circ Res. 2018;123(10):1127–42.PubMedPubMedCentralCrossRef

40.

Marques P, Domingo E, Rubio A, et al. Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. Biomed Pharmacother. 2022;145:112460.PubMedCrossRef

41.

Saavedra YG, Day R, Seidah NG. The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 is needed for the extracellular low density lipoprotein receptor (LDLR) degradation pathway. J Biol Chem. 2012;287(52):43492–501.PubMedCrossRef

42.

Hampton EN, Knuth MW, Li J, Harris JL, Lesley SA, Spraggon G. The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci U S A. 2007;104(37):14604–9.PubMedPubMedCentralCrossRef

43.

Filková M, Haluzík M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol. 2009;133(2):157–70.PubMedCrossRef

44.

Melone M, Wilsie L, Palyha O, Strack A, Rashid S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J Am Coll Cardiol. 2012;59(19):1697–705.PubMedCrossRef

45.

Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS ONE. 2013;8(5):e64145.PubMedPubMedCentralCrossRef

46.

Demers A, Samani S, Lauzier B, et al. PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler Thromb Vasc Biol. 2015;35(12):2517–25.PubMedCrossRef

47.

Poirier S, Mayer G, Poupon V, et al. Dissection of the endogenous cellular pathways of PCSK9-induced LDLR degradation: evidence for an intracellular route. J Biol Chem. 2009;284(42):28856–64.PubMedPubMedCentralCrossRef

48.

• Byun JH, Lebeau PF, Platko K, et al: Inhibitory antibodies against PCSK9 reduce surface CD36 and mitigate diet-induced renal lipotoxicity. Kidney360 2022 (in press): https://doi.org/10.34067/KID.0007022021.(This study suggests that the binding domains that PCSK9 uses to interact and degrade both the LDLR and CD36 are distinct, and that CD36 may rather bind the CHRD of PCSK9•)

49.

Lebeau PF, Byun JH, Platko K, et al. Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. JHEP Rep. 2019;1(6):418–29.PubMedPubMedCentralCrossRef

50.

Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–19.PubMedCrossRef

51.

Strom TB, Tveten K, Leren TP. PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum. Biochem J. 2014;457(1):99–105.PubMedCrossRef

52.

Poirier S, Hamouda HA, Villeneuve L, Demers A, Mayer G. Trafficking dynamics of PCSK9-induced LDLR degradation: focus on human PCSK9 mutations and C-terminal domain. PLoS ONE. 2016;11(6): e0157230.PubMedPubMedCentralCrossRef

53.

Benjannet S, Hamelin J, Chretien M, Seidah NG. Loss- and gain-of-function PCSK9 variants: clevage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J Biol Chem. 2012;287(40):33745–55.PubMedPubMedCentralCrossRef

54.

Lebeau P, Platko K, Al-Hashimi AA, et al. Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained. J Biol Chem. 2018;293(19):7329–43.PubMedPubMedCentralCrossRef

55.

Poirier S, Mamarbachi M, Chen WT, Lee AS, Mayer G. GRP94 regulates circulating cholesterol levels through blockade of PCSK9-induced LDLR degradation. Cell Rep. 2015;13(10):2064–71.PubMedCrossRef

56.

Sakai J, Duncan EA, Rawson RB, Hua X, Brown MS, Goldstein JL. Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment. Cell. 1996;85(7):1037–46.PubMedCrossRef

57.

Seidah NG, Khatib AM, Prat A. The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol Chem. 2006;387(7):871–7.PubMedCrossRef

58.

Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004;24(8):1454–9.PubMedCrossRef

59.

Attie AD, Seidah NG. Dual regulation of the LDL receptor–some clarity and new questions. Cell Metab. 2005;1(5):290–2.PubMedCrossRef

60.

Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res. 2008;49(2):399–409.PubMedCrossRef

61.

• Lebeau PF, Byun JH, Platko K, et al. Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance. Nat Commun. 2022;13(1):770. (Findings from this study suggest that caffeine and some of its xanthine derivatives increase hepatic ER Ca2+ levels, and effectively block de novo synthesis of PCSK9, and reduce its circulating levels in vitro, in vivo, and in healthy volunteers•)PubMedPubMedCentralCrossRef

62.

Seidah NG, Abifadel M, Prost S, Boileau C, Prat A. The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin/kexin 9. Pharmacol Rev. 2017;69(1):33–52.PubMedCrossRef

63.

Al-Mashhadi RH, Sorensen CB, Kragh PM, et al. Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant. Sci Transl Med. 2013;5(166):166ra161.CrossRef

64.

Herbert B, Patel D, Waddington SN, et al. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control. Arterioscler Thromb Vasc Biol. 2010;30(7):1333–9.PubMedCrossRef

65.

Roche-Molina M, Sanz-Rosa D, Cruz FM, et al. Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9. Arterioscler Thromb Vasc Biol. 2015;35(1):50–9.PubMedCrossRef

66.

Peled M, Nishi H, Weinstock A, et al. A wild-type mouse-based model for the regression of inflammation in atherosclerosis. PLoS ONE. 2017;12(3):e0173975.PubMedPubMedCentralCrossRef

67.

Bjørklund MM, Bernal JA, Bentzon JF. Atherosclerosis induced by adeno-associated virus encoding gain-of-function PCSK9. Methods Mol Biol. 2022;2419:461–73.PubMedCrossRef

68.

Seidah NG, Pasquato A, Andréo U. How do enveloped viruses exploit the secretory proprotein convertases to regulate infectivity and spread? Viruses. 2021;13(7):1229.PubMedPubMedCentralCrossRef

69.

Bridge SH, Sheridan DA, Felmlee DJ, et al. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. J Hepatol. 2015;62(4):763–70.PubMedCrossRef

70.

Le QT, Blanchet M, Seidah NG, Labonte P. Plasma membrane CD81 complexes with PCSK9 and LDLR and its levels are reduced by PCSK9. J Biol Chem. 2015;290(38):23385–400.PubMedPubMedCentralCrossRef

71.

Pirro M, Bianconi V, Francisci D, et al. Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism. J Cell Mol Med. 2017;21(12):3150–61.PubMedPubMedCentralCrossRef

72.

Leucker TM, Weiss RG, Schär M, et al. Coronary endothelial dysfunction is associated with elevated serum PCSK9 levels in people with HIV Independent of low-density lipoprotein cholesterol. J Am Heart Assoc. 2018;7(19):e009996.PubMedPubMedCentralCrossRef

73.

Leucker TM, Gerstenblith G, Schär M, et al. Evolocumab, a PCSK9-monoclonal antibody, rapidly reverses coronary artery endothelial dysfunction in people living with HIV and people with dyslipidemia. J Am Heart Assoc. 2020;9(14):e016263.PubMedPubMedCentralCrossRef

74.

Zhang XJ, Qin JJ, Cheng X, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32(2):176-187.e4.PubMedPubMedCentralCrossRef

75.

Pal R, Banerjee M, Yadav U, Bhattacharjee S. Statin use and clinical outcomes in patients with COVID-19: an updated systematic review and meta-analysis. Postgrad Med J. 2022;98(1159):354–9.PubMedCrossRef

76.

Essalmani R, Jain J, Susan-Resiga D, et al. Distinctive roles of furin and TMPRSS2 in SARS-CoV-2 infectivity. J Virol. 2022;96(8):e0012822.PubMedCrossRef

77.

Whitehorn J, Nguyen CVV, Khanh LP, et al. Lovastatin for the treatment of adult patients with dengue: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2016;62(4):468–76.PubMed

78.

Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7.PubMedPubMedCentralCrossRef

79.

Gan ES, Tan HC, Le DHT, et al. Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes. J Clin Invest. 2020;130(10):5223–34.PubMedPubMedCentralCrossRef

80.

Brown MS, Goldstein JL. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89(3):331–40.PubMedCrossRef

81.

Roubtsova A, Munkonda MN, Awan Z, et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) Regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol. 2011;31(4):785–91.PubMedCrossRef

82.

Gelzleichter TR, Halpern W, Erwin R, et al. Combined administration of RG7652, a recombinant human monoclonal antibody against PCSK9, and atorvastatin does not result in reduction of immune function. Toxicol Sci. 2014;140(2):470–80.PubMedCrossRef

83.

•• Liu X, Bao X, Hu M, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588(7839):693–8. (This seminal study suggests that the use of PCSK9i not only reduced LDLc levels but also enhanced the efficacy of cancer immune therapy targeted to the checkpoint protein PD-1••)PubMedPubMedCentralCrossRef

84.

Yuan J, Cai T, Zheng X, et al. Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling. Protein Cell. 2021;12(4):240–60.PubMedPubMedCentralCrossRef

85.

Gangloff A, Calon F, Seidah NG. Can iPCSK9-induced hypocholesterolemia starve cancer cells? J Clin Lipidol. 2017;11(3):600–1.PubMedCrossRef

86.

Sun H, Meng W, Zhu J, Wang L. Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition. Naunyn Schmiedebergs Arch Pharmacol. 2022;395(6):643–58.PubMedCrossRef

87.

Garçon D, Moreau F, Ayer A, et al. Circulating rather than intestinal PCSK9 (proprotein convertase subtilisin kexin type 9) regulates postprandial lipemia in mice. Arterioscler Thromb Vasc Biol. 2020;40(9):2084–94.PubMedCrossRef

88.

• Peyot ML, Roubtsova A, Lussier R, et al. Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866(8):158968. (This study revealed that in mouse the deletion of PCSK9 expression from whole body or in pancreatic β-cells knockout mice does not affect insulin levels or result in any toxic effects on β-cell function and glucose homeostasis. This conclusion agrees with observations from clinical trials of the lack of effects of PCSK9 mAbs on diabetes risk•)PubMedCrossRef

89.

Lei L, Li X, Yuan YJ, et al. Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates 2,4,6-trinitrobenzenesulfonic acid-induced colitis via repressing Toll-like receptor 4/nuclear factor-kappa B. Kaohsiung J Med Sci. 2020;36(9):705–11.PubMedCrossRef

90.

Jiang J, Natarajan K, Margulies DH. MHC Molecules, T cell receptors, natural killer cell receptors, and viral immunoevasins-key elements of adaptive and innate immunity. Adv Exp Med Biol. 2019;1172:21–62.PubMedCrossRef

91.

Böhm W, Thoma S, Leithäuser F, Möller P, Schirmbeck R, Reimann J. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol. 1998;161(2):897–908.PubMed

92.

Roudaut M, Idriss S, Caillaud A, et al. PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs. Stem Cell Reports. 2021;16(12):2958–72.PubMedPubMedCentralCrossRef

93.

Dlugosz P, Nimpf J. The reelin receptors apolipoprotein E receptor 2 (ApoER2) and VLDL receptor. Int J Mol Sci. 2018;19(10):3090.PubMedCentralCrossRef

Titel: Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
verfasst von: Nabil G. Seidah
Damien Garçon
Publikationsdatum: 29.07.2022
Verlag: Springer US
Erschienen in: Current Atherosclerosis Reports / Ausgabe 10/2022
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-022-01057-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Auf Antibiotika verzichten? Was bei unkomplizierter Zystitis hilft

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO₂. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era

Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention

Inclisiran: How Widely and When Should We Use It?

Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?

Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women